Top Markets
#1 Black Phoenix Black Phoenix +21,376.82%
#2 Nesa Nesa +742.64%
#3 ADO Protocol ADO Protocol +103.82%
#4 Cortex Cortex +95.56%
#5 Ontology Gas Ontology Gas +85.65%
#6 Kinesis Silver Kinesis Silver +53.16%
#7 Magma Finance Magma Finance +30.19%
#8 OpenEden OpenEden +29.92%
#9 PondCoin PondCoin +27.37%
#10 Pons Pons +24.66%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Pacific Edge Limited Pacific Edge Limited

Pacific Edge Limited

PEB
Rangering i aksjer #18664
Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001,... Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed at the early identification and ongoing management of various cancers. Its diagnostic solutions are accessible in New Zealand, the United States, Australia, and Singapore, with operations structured across Commercial and Research segments. A key offering is the Cxbladder suite, a collection of genomic urine tests specifically designed for detecting and managing bladder cancer. Within this suite, Cxbladder Resolve aids in identifying patients likely to present with more aggressive or advanced bladder cancer. Cxbladder Triage helps pinpoint individuals with haematuria who exhibit a low probability of bladder cancer, while Cxbladder Detect offers a non-invasive method for identifying bladder and other urinary tract cancers. Furthermore, Cxbladder Monitor facilitates continuous surveillance for disease recurrence in bladder cancer patients. Beyond its focus on bladder cancer, Pacific Edge is actively developing additional diagnostic innovations. These include Cxcolorectal, a prognostic gene signature for assessing outcomes in patients diagnosed with stage II or stage III colorectal cancers, alongside pipeline products targeting gastric, endometrial cancers, and melanoma.
Aksjekurs
$0.15360289
Markedsverdi
$190.75M
Endring (1 dag)
6.25%
Endring (1 år)
94.11%
Land
NZ
Handel Pacific Edge Limited (PEB)

Kategori

Healthcare
P/E-forhold for Pacific Edge Limited (PEB)
P/E-forhold per 2026 TTM: 0
Ifølge Pacific Edge Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Pacific Edge Limited fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 31.59 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 35.83 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -227.89 -
US
Agilent Technologies, Inc. Agilent Technologies, Inc.
Agilent Technologies, Inc.
A.US
 29.77 -
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.